Literature DB >> 6318994

Etoposide (VP-16) in the treatment of lung cancer.

A G Pedersen, H H Hansen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6318994     DOI： 10.1016/0305-7372(83)90013-0

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  8 in total

Review 1.  Chemotherapy in lung cancer.

Authors:  C G Price; M L Slevin
Journal:  Postgrad Med J       Date:  1989-05       Impact factor: 2.401

2.  Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide.

Authors:  G M Mead; J Thompson; J W Sweetenham; R B Buchanan; J M Whitehouse; C J Williams
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer.

Authors:  S Pashko; D H Johnson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

4.  Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study.

Authors:  C Collins; C S Higano; R B Livingston; B R Griffin; M D Keppen; T P Miller
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.

Authors:  H Roed; L L Vindelov; I J Christensen; M Spang-Thomsen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 6.  Teniposide: overview of its therapeutic potential in adult cancers.

Authors:  F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.

Authors:  V J Harvey; M L Slevin; S P Joel; A Johnston; P F Wrigley
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

8.  Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.

Authors:  H Gogas; F J Lofts; T R Evans; F J Millard; R Wilson; J L Mansi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.